Advanced

mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia

Sebastianutto, Irene LU and Cenci, Maria Angela LU (2018) In Current Opinion in Pharmacology 38. p.81-89
Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by typical motor features that result from dopamine (DA) depletion in the striatum. DA replacement therapy with L-DOPA is the most efficacious symptomatic treatment, but causes complications that limit its utility, in particular, L-DOPA-induced dyskinesia (LID). LID is primarily caused by pre-synaptic and post-synaptic changes in DA neurotransmission, although it also depends on altered glutamatergic transmission at several nodes of the cortico-basal ganglia-thalamocortical network. The important functional interplay between dopaminergic and glutamatergic systems has stimulated an interest in metabotropic glutamate receptors (mGluRs) as potential therapeutic targets... (More)

Parkinson's disease (PD) is a neurodegenerative disorder characterized by typical motor features that result from dopamine (DA) depletion in the striatum. DA replacement therapy with L-DOPA is the most efficacious symptomatic treatment, but causes complications that limit its utility, in particular, L-DOPA-induced dyskinesia (LID). LID is primarily caused by pre-synaptic and post-synaptic changes in DA neurotransmission, although it also depends on altered glutamatergic transmission at several nodes of the cortico-basal ganglia-thalamocortical network. The important functional interplay between dopaminergic and glutamatergic systems has stimulated an interest in metabotropic glutamate receptors (mGluRs) as potential therapeutic targets in PD and LID. We here review the antiparkinsonian and antidyskinetic potential of modulating group I, II, and III mGluRs in several preclinical models of PD. We also provide an update on clinical trials evaluating mGluR5 or mGluR4 ligands in PD.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Current Opinion in Pharmacology
volume
38
pages
9 pages
publisher
Elsevier
external identifiers
  • scopus:85044742293
ISSN
1471-4892
DOI
10.1016/j.coph.2018.03.003
language
English
LU publication?
yes
id
231b3e1e-4105-415a-ad20-085d4b9af7f7
date added to LUP
2018-04-11 14:40:43
date last changed
2019-04-23 04:31:04
@article{231b3e1e-4105-415a-ad20-085d4b9af7f7,
  abstract     = {<p>Parkinson's disease (PD) is a neurodegenerative disorder characterized by typical motor features that result from dopamine (DA) depletion in the striatum. DA replacement therapy with L-DOPA is the most efficacious symptomatic treatment, but causes complications that limit its utility, in particular, L-DOPA-induced dyskinesia (LID). LID is primarily caused by pre-synaptic and post-synaptic changes in DA neurotransmission, although it also depends on altered glutamatergic transmission at several nodes of the cortico-basal ganglia-thalamocortical network. The important functional interplay between dopaminergic and glutamatergic systems has stimulated an interest in metabotropic glutamate receptors (mGluRs) as potential therapeutic targets in PD and LID. We here review the antiparkinsonian and antidyskinetic potential of modulating group I, II, and III mGluRs in several preclinical models of PD. We also provide an update on clinical trials evaluating mGluR5 or mGluR4 ligands in PD.</p>},
  author       = {Sebastianutto, Irene and Cenci, Maria Angela},
  issn         = {1471-4892},
  language     = {eng},
  month        = {02},
  pages        = {81--89},
  publisher    = {Elsevier},
  series       = {Current Opinion in Pharmacology},
  title        = {mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia},
  url          = {http://dx.doi.org/10.1016/j.coph.2018.03.003},
  volume       = {38},
  year         = {2018},
}